日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.

从患者角度评估 3 期转移性去势抵抗性前列腺癌临床试验中的不良事件

Dueck Amylou C, Scher Howard I, Bennett Antonia V, Mazza Gina L, Thanarajasingam Gita, Schwab Gisela, Weitzman Aaron L, Rogak Lauren J, Basch Ethan

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

卡博替尼对比米托蒽醌-泼尼松治疗有症状的转移性去势抵抗性前列腺癌:一项以疼痛为主要终点的随机3期试验

Basch, Ethan M; Scholz, Mark; de Bono, Johann S; Vogelzang, Nicholas; de Souza, Paul; Marx, Gavin; Vaishampayan, Ulka; George, Saby; Schwarz, James K; Antonarakis, Emmanuel S; O'Sullivan, Joseph M; Kalebasty, Arash Rezazadeh; Chi, Kim N; Dreicer, Robert; Hutson, Thomas E; Dueck, Amylou C; Bennett, Antonia V; Dayan, Erica; Mangeshkar, Milan; Holland, Jaymes; Weitzman, Aaron L; Scher, Howard I

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

卡博替尼治疗晚期前列腺癌患者:一项 II 期随机停药试验的结果

Smith, David C; Smith, Matthew R; Sweeney, Christopher; Elfiky, Aymen A; Logothetis, Christopher; Corn, Paul G; Vogelzang, Nicholas J; Small, Eric J; Harzstark, Andrea L; Gordon, Michael S; Vaishampayan, Ulka N; Haas, Naomi B; Spira, Alexander I; Lara, Primo N Jr; Lin, Chia-Chi; Srinivas, Sandy; Sella, Avishay; Schöffski, Patrick; Scheffold, Christian; Weitzman, Aaron L; Hussain, Maha